Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ATAD2 is an E2F target gene that is highly expressed in gastrointestinal and breast carcinomas. Here we characterize a related gene product,
ATAD2B
. Both genes are evolutionarily conserved, with orthologues present in all eukaryotic genomes examined. Human
ATAD2B
shows a high degree of similarity to ATAD2. Both contain an AAA domain and a bromodomain with amino acid sequences sharing 97% and 74% identity, respectively. The expression of
ATAD2B
was studied in the chicken embryo using a polyclonal antibody raised against a recombinant fragment of human
ATAD2B
. Immunohistochemistry revealed transient nuclear expression in subpopulations of developing neurons. The transient nature of the expression was confirmed by immunoblotting homogenates of the developing telencephalon. Cell fractionation was used to confirm the nuclear localization of
ATAD2B
in the developing nervous system: anti-
ATAD2B
recognizes a smaller band (approximately 160 kDa) in the nuclear fraction and a larger band (approximately 300 kDa) in the membrane fraction, suggesting that posttranslational processing of
ATAD2B
may regulate its transport to the nucleus. The expression of
ATAD2B
was also studied in human tumors. Oncomine and immunohistochemistry reveal
ATAD2B
expression in
glioblastoma
and oligodendroglioma;
ATAD2B
immunostaining was also elevated in human breast carcinoma. In tumors
ATAD2B
appears to be cytoplasmic or membrane bound, and not nuclear. Our observations suggest that
ATAD2B
may play a role in neuronal differentiation and tumor progression.
...
PMID:ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. 2115 54